Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure

Tardif, J.‐C. et al. (2023) Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure. ESC Heart Failure, 10(2), pp. 1066-1076. (doi: 10.1002/ehf2.14268) (PMID:36564955)

[img] Text
288486.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.



Aims: Several patients with heart failure and reduced ejection fraction (HFrEF) do not receive renin–angiotensin–aldosterone system (RAAS) inhibitors at the recommended dose or at all, frequently due to actual or feared hyperkalaemia. Sodium zirconium cyclosilicate (SZC) is an orally administered non-absorbed intestinal potassium binder proven to lower serum potassium concentrations. Methods and results: PRIORITIZE-HF was an international, multicentre, parallel-group, randomized, double-blind, placebo-controlled study to evaluate the benefits and risks of using SZC to intensify RAAS inhibitor therapy. Patients with symptomatic HFrEF were eligible and randomly assigned to receive SZC 5 g or placebo once daily for 12 weeks. Doses of study medication and RAAS inhibitors were titrated during the treatment period. The primary endpoint was the proportion of patients at 12 weeks in the following categories: (i) any RAAS inhibitor at less than target dose, and no MRA; (ii) any RAAS inhibitor at target dose and no MRA; (ii) MRA at less than target dose; and (iv) MRA at target dose. Due to challenges in participant management related to the COVID-19 pandemic, the study was prematurely terminated with 182 randomized patients. There was no statistically significant difference in the distribution of patients by RAAS inhibitor treatment categories at 3 months (P = 0.43). The proportion of patients at target MRA dose was numerically higher in the SZC group (56.4%) compared with the placebo group (47.0%). Overall, SZC was well tolerated. Conclusions: PRIORITIZE-HF was terminated prematurely due to COVID-19 and did not demonstrate a statistically significant increase in the intensity of RAAS inhibitor therapies with the potassium-reducing agent SZC compared with placebo.

Item Type:Articles
Additional Information:This work was supported by AstraZeneca.
Keywords:Heart failure with reduced ejection fraction, RAAS inhibitors, guideline‐directed medical therapy, hyperkalaemia, sodium zirconium cyclosilicate.
Glasgow Author(s) Enlighten ID:McMurray, Professor John
Authors: Tardif, J.‐C., Rouleau, J., Chertow, G. M., Al‐Shurbaji, A., Lisovskaja, V., Gustavson, S., Zhao, Y., Bouabdallaoui, N., Desai, A. S., Chernyavskiy, A., Evsina, M., Merkely, B., McMurray, J. J.V., and Pfeffer, M. A.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Journal Name:ESC Heart Failure
ISSN (Online):2055-5822
Published Online:23 December 2022
Copyright Holders:Copyright © 2022 The Authors
First Published:First published in ESC Heart Failure 10(2): 1066-1076
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record